7.4 Myeloproliferative Disorders

Key Takeaways

  • Persistent unexplained erythrocytosis, thrombocytosis or myeloid leucocytosis warrants a review of previous blood counts, blood film and secondary causes.

  • Polycythaemia vera usually has a JAK2 variant. A low erythropoietin level and elevation of other myeloid cell lines support the diagnosis.

  • Persistent thrombocytosis may be reactive or clonal. Driver mutation testing and marrow morphology help distinguish essential thrombocythaemia from other myeloid neoplasms.

  • A left-shifted myeloid leucocytosis with basophilia raises suspicion of chronic myeloid leukaemia. Confirm BCR::ABL1 and refer to haematology.

  • Anaemia, splenomegaly and a leucoerythroblastic film raise concern for myelofibrosis or another infiltrative marrow process.

Last updated: November 2026

Decide when a high blood count needs haematology review

Myeloproliferative neoplasms are clonal disorders of blood-forming cells. An isolated raised count is more commonly explained by a reactive or secondary cause in many primary-care settings. Review previous results, repeat a new unexplained abnormality when clinically appropriate and examine the rest of the full blood count and the film. Look for splenomegaly, weight loss, drenching sweats, pruritus, thrombosis and bleeding. An acute thrombotic or bleeding complication requires emergency assessment alongside investigation of the count.

Dominant findingCommon alternatives or initial checksClue to a clonal process
High haemoglobin or haematocritCheck hydration and persistence. Review smoking, hypoxia, sleep apnoea, cardiopulmonary disease and testosterone or other relevant drugs.Persistent erythrocytosis with raised platelets or neutrophils, splenomegaly, low erythropoietin or otherwise unexplained thrombosis.
High platelet countLook for iron deficiency, infection, inflammation, recent surgery, splenectomy and malignancy.Persistent unexplained thrombocytosis, thrombosis, splenomegaly or another abnormal cell line.
High white cell countReview acute infection, inflammation, medicines and film morphology.Persistent left-shifted granulocytosis with basophilia raises suspicion of CML.
Anaemia with immature myeloid and erythroid cells in bloodConsider marrow infiltration or severe physiological stress in context.A leucoerythroblastic film with tear-drop red cells and splenomegaly raises suspicion of myelofibrosis.

The Irish NCCP adult referral manual uses clinical findings and trends to decide urgency. For example, its urgent outpatient erythrocytosis pathway includes haematocrit of at least 0.52 L/L in men or 0.48 L/L in women when accompanied by leucocytosis or thrombocytosis, arterial or venous thrombosis, or splenomegaly. Use the emergency pathway for an active complication. Tell haematology about the time course, count and film, iron studies or inflammatory markers where relevant, oxygenation and medication history. Molecular findings are interpreted with clinical and marrow features.

NCCP 2026 adult haematology referral manual · WHO fifth edition myeloid classification

Erythrocytosis and thrombocytosis

Polycythaemia vera (PV) can cause persistent erythrocytosis with leucocytosis or thrombocytosis, headaches, aquagenic pruritus or splenomegaly. It increases arterial and venous thrombotic risk. Splanchnic venous thrombosis can be a clue. JAK2 V617F is the usual driver, and some patients have an exon 12 variant. A low erythropoietin level supports PV, while hypoxia and other secondary causes still need assessment. Specialist diagnosis can incorporate marrow panmyelosis. Iron deficiency may reduce MCV and obscure the extent of erythrocytosis.

Once PV is confirmed, haematology aims to reduce thrombosis. Venesection and, for selected patients, cytoreduction can maintain haematocrit below 45%. Low-dose aspirin is commonly used when suitable. Assess bleeding risk and individual indications before giving it. CYTO-PV compared a target below 45% with 45–50% and found fewer cardiovascular deaths or major thrombotic events with the lower target. That target belongs to PV management.

Essential thrombocythaemia (ET) is a clonal disorder with persistent thrombocytosis. Iron deficiency and inflammation are important alternatives. JAK2, CALR or MPL variants support a clonal cause. A negative driver panel leaves clonal disease possible. Marrow morphology helps distinguish ET from prefibrotic myelofibrosis and other myeloid disorders. Both thrombosis and bleeding matter. Marked thrombocytosis can be associated with acquired von Willebrand syndrome. Aspirin and cytoreduction depend on thrombotic and bleeding risk and specialist review.

Worked example. A patient has thrombocytosis during a lower respiratory infection. The previous platelet count was normal, inflammatory markers are raised and the film has no concerning immature cells. The first step is to treat the illness and recheck the count. If thrombocytosis persists without an explanation, reassess iron status and seek haematology advice.

BSH polycythaemia vera guideline · CYTO-PV trial · Low-dose aspirin trial in PV · BSH thrombocytosis without the common driver variants

Recognise myelofibrosis and chronic myeloid leukaemia

Primary myelofibrosis can present with fatigue, anaemia, weight loss, night sweats, abdominal fullness from splenomegaly and a leucoerythroblastic film. The film can also show tear-drop cells. A similar picture can occur in secondary myelofibrosis after PV or ET or with another marrow disorder. Haematology uses a marrow trephine, molecular testing and clinical findings to distinguish these possibilities. Management depends on risk, symptoms and fitness. JAK inhibitors can improve splenomegaly and disease symptoms in selected patients. Some higher-risk patients should be assessed for allogeneic stem-cell transplantation.

Chronic myeloid leukaemia (CML) is defined by the BCR::ABL1 fusion, classically associated with the Philadelphia chromosome. Consider it when neutrophilic leucocytosis spans multiple stages of myeloid maturation and basophilia is present. Splenomegaly can accompany the blood findings. Reactive neutrophilia can also produce a left shift, so use the clinical context and appropriate testing. Arrange haematology assessment for confirmation using molecular or cytogenetic testing. In chronic-phase CML, tyrosine kinase inhibitors target BCR::ABL1. Serial quantitative molecular testing measures response. The ELN tailors drug choice to disease features, comorbidities, reproductive plans and adverse effects.

BSH myelofibrosis diagnosis · BSH myelofibrosis management · ASH 2026 myelofibrosis guidance · EBMT/ELN myelofibrosis transplant recommendations · ELN 2025 CML recommendations

Test Your Knowledge

A 59-year-old has persistent haematocrit of 0.56, a platelet count of 535 × 10⁹/L, itching after hot showers and palpable splenomegaly. Oxygen saturation is normal and serum erythropoietin is low. Which diagnosis and investigation are most appropriate?

A

Iron deficiency alone. Start iron and repeat a full blood count in one year.

B

Secondary erythrocytosis due to hypoxia. Start long-term oxygen without further investigation.

C

Suspected polycythaemia vera. Arrange urgent outpatient haematology assessment for diagnostic work-up including JAK2 testing.

D

Confirmed essential thrombocythaemia. Start aspirin based on the platelet count alone.

Test Your Knowledge

A 49-year-old has splenomegaly and persistent leucocytosis. The film shows neutrophils across several stages of maturation and increased basophils. There is no current infection. Which next investigation directly tests the leading clonal diagnosis?

A

BCR::ABL1 testing for suspected chronic myeloid leukaemia

B

An intrinsic factor antibody test for suspected autoimmune gastritis

C

ADAMTS13 activity for suspected thrombotic thrombocytopenic purpura

D

A direct antiglobulin test for suspected warm autoimmune haemolysis

Sections you finish are checked off in the contents.